Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

October 31, 2009

Study Completion Date

December 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Saxagliptin

5 mg, oral tablet, once daily

DRUG

Metformin

500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy

Trial Locations (51)

Unknown

Research Site, Brussels (woluwe-st-lambert)

Research Site, Halen

Research Site, Lommel

Research Site, Oostham

Research Site, Sint-Gillis-Waas

Research Site, Zoersel

Research Site, Bruges

Research Site, Moerkerke

Research Site, Tielt

Research Site, Châtellerault

Research Site, Corbeil-Essonnes

Research Site, La Rochelle

Research Site, La Seyne-sur-Mer

Research Site, Paris

Research Site, Seysses

Research Site, Tiercé

Research Site, Berlin

Research Site, Freiburg im Breisgau

Research Site, Leipzig

Research Site, Ludwigshafen

Research Site, Mannheim

Research Site, Rhaunen

Research Site, Schmiedeberg

Research Site, Wahlstedt

Research Site, Bergamo

Research Site, Forlì

Research Site, Milan

Research Site, Padua

Research Site, Pordenone

Research Site, Siena

Research Site, Roma

Research Site, Seville

Research Site, Barcelona

Research Site, A Coruña

Research Site, Madrid

Research Site, San Sebastián de los Reyes

Research Site, Oviedo

Research Site, Alicante

Research Site, Ankara

Research Site, Bursa

Research Site, Kırıkkale

Research Site, Ankara

Research Site, Reading

Research Site, Atherstone

Research Site, Royal Leamington Spa

Research Site, Warminster

Research Site, Westbury

Research Site, Ashford

Research Site, Bath

Research Site, Coventry

Research Site, Peterborough

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY